Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a pioneering United States-based biotechnology company dedicated to combating cancers and infectious diseases through DNA medicines. The company's innovative approach harnesses active DNA-based immunotherapies and vaccines to both treat and prevent these conditions.
Inovio's core technology revolves around its DNA plasmids, which are small circular DNA molecules crafted to produce specific proteins to target and fight diseases, delivered via their proprietary CELLECTRA® electroporation devices. This technology enables the body to produce its own disease-fighting proteins and immune responses, without the need for traditional adjuvants or nanoparticles.
The company's flagship candidate, INO-3107, targets Recurrent Respiratory Papillomatosis (RRP), a chronic and rare disease caused by HPV-6 and HPV-11. Inovio has shown significant clinical progress with INO-3107, and after receiving Breakthrough Therapy designation and Orphan Drug designation from both the FDA and the European Commission, it is on track to submit a Biologics License Application (BLA) under the FDA's accelerated approval program. With successful clinical trials demonstrating a robust immune response and a reduction in the need for surgical interventions, INO-3107 stands as a potential game-changer for RRP patients.
In addition to INO-3107, Inovio's expansive product pipeline includes several other promising candidates in various stages of development. These include INO-3112 for HPV-16/18 positive head and neck cancer, INO-4201 as an Ebola vaccine booster, and INO-5401 for glioblastoma, showcasing the versatility and broad applicability of the company's DNA medicine platform.
Inovio has established numerous strategic partnerships and collaborations to enhance its research and development efforts. Key partners include Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, and the U.S. Military HIV Research Program. These collaborations not only bolster Inovio's scientific capabilities but also facilitate the swift advancement of its clinical programs.
Financially, Inovio has maintained a disciplined approach to managing its resources. The company recently projected its cash runway to extend into the second quarter of 2025, following positive feedback from the FDA on the accelerated approval pathway for INO-3107. This financial stability is crucial as Inovio prepares for potential commercialization of its lead candidates.
Inovio's commitment to innovation and its effective strategic execution position it as a formidable player in the biopharmaceutical industry, dedicated to bringing groundbreaking DNA medicine solutions to market. For more information, visit www.inovio.com.
INOVIO reported Q3 2024 financial results and updates on INO-3107 development for RRP treatment. New immunology data showed INO-3107's ability to induce T cell responses against HPV-6 and HPV-11. The Phase 1/2 trial demonstrated 81% clinical response rate, with 28% of patients requiring no surgical intervention. Financial highlights include cash position of $84.8M, R&D expenses of $18.7M, and net loss of $25.2M. The company targets BLA submission for mid-2025, with all non-device modules expected to be completed by end of 2024. Cash runway is projected into Q3 2025.
INOVIO announced new immunology data supporting the clinical activity of INO-3107 in treating recurrent respiratory papillomatosis (RRP). The data shows INO-3107 induced expansion of new clonal T cells in blood that weren't detectable before treatment. These cells traveled to papilloma and airway tissues, generating an inflammatory and anti-viral response consistent with reduced surgery needs for RRP patients with HPV-6 and HPV-11. The Phase 1/2 trial's immunological testing demonstrated the drug's ability to induce T cell responses specific to HPV-6 and HPV-11, including cytotoxic CD8+ T cells present at week 52, indicating memory response establishment.
INOVIO (NASDAQ:INO) announced its participation in two major scientific conferences. At the 36th International Papillomavirus Conference in Edinburgh (Nov 12-15), the company will present research on INO-3107's treatment of recurrent respiratory papillomatosis, including studies on interferon responses and T-cell activity. At the Vaccines Summit in Boston (Nov 13-15), Dr. Dave Liebowitz will deliver a keynote on DNA Medicines Vaccine Platform, focusing on Ebola and respiratory papillomatosis case studies. All conference abstracts will be available on INOVIO's website after presentations.
INOVIO (NASDAQ: INO), a biotechnology company focused on DNA medicines for HPV-associated diseases, cancer, and infectious diseases, announced it will release its third quarter 2024 financial results after market close on November 14, 2024. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring a Q&A session with analysts. The webcast will be accessible at the company's investor relations website and will remain available for replay for 90 days.
INOVIO (NASDAQ:INO) presented new data for its lead candidate, INO-3107, at scientific conferences. The company is preparing a Biologics License Application for targeted submission in mid-2025 under the FDA's Accelerated Approval Pathway Program. New immunology data showed INO-3107's ability to induce antigen-specific T cell responses against HPV-6 and HPV-11 and drive T cell recruitment into airway tissues and papilloma of RRP patients.
In the Phase 1/2 trial, INO-3107 was well-tolerated and immunogenic. 81% of patients experienced a decrease in surgical interventions post-treatment compared to baseline. The overall clinical response was 81%, with 28% of patients requiring no surgical intervention during or after the dosing window. 44% of patients had a partial response, resulting in an overall response rate of 72%.
INO-3107 induced durable cellular responses and generated T cells against HPV-6 and HPV-11. The company believes these data demonstrate INO-3107's potential to significantly improve the lives of RRP patients.
INOVIO (NASDAQ:INO), a biotechnology company focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases, has announced equity grants under its 2022 Inducement Plan. The Compensation Committee approved awards to two newly hired employees, including:
1. Restricted stock units (RSUs) covering 1,526 shares of common stock
2. Options to purchase 1,600 shares of common stock
The grants, dated September 30, 2024, include RSUs vesting over three years and stock options with an exercise price of $5.78. The stock options will vest in four installments, with one-fourth vesting immediately and the remainder annually over three years. Both RSUs and options are subject to continued employment and specific agreement terms under the Inducement Plan.
INOVIO (NASDAQ:INO), a biotechnology company developing DNA medicines, announced its participation in four upcoming scientific conferences. These include:
1. AACR Special Conference in Boston, MA (Oct 19, 2024): Dr. Matthew Morrow will present a poster on INO-3107's impact on reducing surgical interventions for Recurrent Respiratory Papillomatosis (RRP).
2. ISV Congress 2024 in Seoul, Korea (Oct 22, 2024): Dr. Michael Sumner will give an oral presentation and poster on the clinical assessment of INO-3107 in adult RRP patients.
3. Fall Voice in Phoenix, AZ (Oct 25-26, 2024): Dr. Jeffrey Skolnik will present a poster on the clinical assessment of INO-3107 in adult RRP patients.
4. World Vaccine Congress Europe in Barcelona, Spain (Oct 28, 2024): Dr. Dave Liebowitz will give a presentation and participate in a panel discussion on platform technologies.
Abstracts from these conferences will be available on INOVIO's website after each presentation.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the World Congress of Electroporation on September 18, 2024, in Rome, Italy. Trevor Smith, VP of Preclinical R&D at INOVIO, will deliver an oral presentation titled 'Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology' at 3:20pm CET.
This presentation aligns with INOVIO's focus on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company plans to make the abstract available on its website after the presentation, providing insights into their innovative approach using CELLECTRA® electroporation technology for DNA-encoded antibodies.
INOVIO (NASDAQ:INO) released its Q2 2024 financial results and recent business updates. Key developments include progress with INO-3107 for RRP, despite identifying a manufacturing issue delaying the BLA submission to mid-2025. All non-device elements of the BLA package are expected to be completed by year-end. The company plans to initiate confirmatory and redosing trials and advance regulatory efforts in Europe and the UK.
INO-3112 Phase 3 trial design submitted to European authorities, addressing HPV-16/-18 related throat cancer. INO-4201 Phase 2/3 clinical trial protocol resubmission to the FDA anticipated in Q3 2024.
Financial highlights: Cash and equivalents at $110.4M, down from $145.3M at the start of the year. R&D expenses were $23.1M, with a net loss of $32.2M this quarter. INOVIO's cash runway extends into Q3 2025 after raising $33.2M in a stock offering.
Steve Egge joined as Chief Commercial Officer to aid in commercial strategy and operations.
INOVIO (NASDAQ:INO) announced an equity grant under its 2022 Inducement Plan to a newly hired employee. The Compensation Committee of INOVIO's Board of Directors approved the award of 9,307 restricted stock units (RSUs) and an option to purchase 12,100 shares of common stock, effective July 31, 2024. The RSUs will vest over three years, with one-third vesting annually starting on the first anniversary of the grant date. The stock option has an exercise price of $10.66, INOVIO's closing price on the grant date, and will vest in four parts: one-fourth on the grant date and the rest annually over the next three years. Vesting is contingent on continued employment. These awards are governed by the terms of a stock option agreement and RSU award agreement under the Inducement Plan.
FAQ
What is the current stock price of Inovio Pharmaceuticals (INO)?
What is the market cap of Inovio Pharmaceuticals (INO)?
What is Inovio Pharmaceuticals' primary focus?
What is INO-3107?
What is the CELLECTRA® device?
Who are some of Inovio’s key partners?
What financial outlook has Inovio projected?
What is INO-3112?
How does Inovio's DNA medicines platform work?
What are some of Inovio’s recent achievements?
Where can I find more financial information about Inovio?
What is Inovio's approach to commercialization?
